The global oral macromolecular formulation market was valued at around US$ 15.7 Mn in 2020, and is expected to exhibit a steady CAGR of around 5.1% over the forecast period (2021-2031).
There are various problems associated with injections, such as pain and needle stick injuries. These issues can be overcome by various ways, and oral route of drug administration is one of them.
- For instance, according to CDC, in the U.S., the annual number of sharp injuries among healthcare workers (HCWs) is 385,000.
Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/32388
Biologics play a valuable role in the treatment of numerous health conditions such Crohn’s disease, ulcerative colitis, rheumatoid arthritis, and other autoimmune diseases, but its delivery is difficult due to its large molecular weight and associated costs that tend to be greater than those of small-molecule drugs. Also, biologics have high specificity and low toxicity as compared to small molecules. Oral route of administration of biologics is crucial in the field of therapeutics due to its non-invasiveness, patient compliance, and convenience of drug administration.
Oral formulation of macromolecules will be primarily beneficial for the geriatric population, especially those suffering from diabetes, because they need regular administration of insulin.
Although the market in not very consolidated, still, there are a few players who are focusing on expansion in emerging regions, doing promotional activities, agreements, partnerships, and collaborations to further strengthening their market presence.
- Oral insulin, (Capsulin™) by Diabetelogy successfully completed 25,000 dosing events in a phase 2b study in early stage type 2 diabetic patients. The phase 2b study shows that capsule formulations can achieve statistically significant changes in key parameters.
Company Profiles:
- Catalent Inc.
- Diabetology Ltd
- UPM Pharmaceuticals
Request for Methodology@ https://www.persistencemarketresearch.com/methodology/32388
Key Takeaways from Market Study
- By indication, inflammatory bowel disorder is set to hold around 45% market value share globally.
- Biopharmaceutical companies are set to dominate with a market share of 83% over the forecast period.
- By region, North America is projected to dominate the global market with a value share of around 55%.
“Increasing demand for biologics and technological advancements are promoting effective product development,” says an analyst of Persistence Market Research.
Access Full Report@ https://www.persistencemarketresearch.com/checkout/32388
Market Competition
Collaborations and partnerships have emerged as a key growth strategy adopted by industry players. By focusing on these strategies, market stakeholders are expanding their geographic footprint and strengthening their presence.
- In December 2020, UPM Pharmaceuticals announced a partnership with RedHill Biopharma Ltd., which will benefit RedHill’s novel, first-in-class, orally administered Phase 3-stage drug candidate under development for severe COVID-19 pneumonia.
What Does the Report Cover?
Persistence Market Research offers a unique perspective and actionable insights on the Oral macromolecular formulation market in its latest study, presenting a historical demand assessment of 2016 – 2020 and projections for 2021 – 2031.
The research study is based on the indication (inflammatory bowel disorder, diabetes, and others) and end user (biopharmaceutical companies and academic and research institutes), across key regions of the world.
About Us: Persistence Market Research
Contact Us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com